Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.

Abstract

BACKGROUND:

Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry.

METHODS:

Heregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor-positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria.

RESULTS:

Among 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive.

CONCLUSION:

Using a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials.

TRIAL REGISTRATION:

Clinicaltrials, NCT02338167 , Registered 14 January 2015 - retrospectively registered.

• Authors: Hanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, Andreas D Hartkopf, Michael P Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A Fasching, Wolfgang Janni, Tanja N Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Johannes Ettl
• Journal: BMC cancer (BMC Cancer) Vol. 20 Issue 1 Pg. 1091 (Nov 11 2020) ISSN: 1471-2407 [Electronic] England
• PMID: 33176725 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Biomarkers, Tumor
• NRG1 protein, human
• Neuregulin-1

Topics

• Adult
• Antibodies, Monoclonal (immunology)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (immunology, metabolism)
• Case-Control Studies
• Clinical Trials as Topic
• Female
• Follow-Up Studies
• Germany
• Humans
• Middle Aged
• Neoplasms (drug therapy, immunology, metabolism, pathology)
• Neuregulin-1 (immunology, metabolism)
• Patient Selection
• Pregnancy
• Pregnancy Complications, Neoplastic (drug therapy, immunology, metabolism, pathology)
• Prognosis
• Prospective Studies
• Registries (statistics & numerical data)
• Survival Rate